Effects of aldosterone and spironolactone on the isolated perfused rat heart

Pharmacology

Volumn 53, Issue 1, 1996, Pages 28-36

  Moreau, D ^a   Charcligny, J M ^b   Rochette, L ^a  

^a Facultés de Médecine et de Pharmacie   (France)

^b CEMAGREF   (France)

Author keywords

Aldosterone; Cardiac function, rat; Spironalactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; SPIRONOLACTONE;

ANIMAL TISSUE; AORTA FLOW; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART FUNCTION; HEART OUTPUT; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029817735     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139412     Document Type: Article

References (46)

1. Weber KT, Brilla CG: Pathological hypertrophy and cardiac intersli-tium fibrosis and renin-angiotensin-aldosterone system, Circulation 1991:83:1849-1865.
2. Klug D, Robert V, Swynghcdauw B: Role of mechanical and hormonal factors in cardiac remodeling and biologic limits of myocardial adaptation, Am J Cardiol 1993:71:46A-54A.
3. Strecten DHP, Hirschowitz BI, Henley KS, Pollard HM: Effects of adrenocortical steroids on the propulsive motility of small intestine, Am J Physiol 1957:189:108-112.
4. Tanz RD: Studies on the inotropic action of aldosterone on isolated cardiac tissue preparation including the effect of pH, ouabain and SC 8109, J Pharmacol Exp Ther 1962: 135:71-78.
5. Yamakado M, Ishii M: Effect of aldosterone on vasculature reactivity to norepinephrine in nephrccto-mized-adrenalectomized rats; in Mantero F, Takeda R, Scoggins BA, Biglieri EG, Funder JW (cds): The Adrenal and Hypertension: From Cloning to Clinic, New York, Raven Press, Screno Symposia Publications, 1989, vol 57, pp 473-477.
6. Hollander W: Aldosterone antagonists in arterial hypertension, Heart Bull 1963:12:108-110.
7. Winer BM, Lubbc WF, Colton T: Antihypertensive action of diuretics, JAMA 1968;204:117-121.
8. Tanz RD, Kerby CF: The inotropic action of certain steroids upon isolated cardiac tissue: With comments on steroidal cardiotonic structure-activity relationships, J Pharmacol Exp Ther 1961:131:56-64.
9. Ullrick WC, Hazelwood RL: Influence of aldosterone on isometric tension development in the rat heart, Am J Physiol 1963:204:1001-1004.
10. Briggs AH, Holland WC: Antifibril-latory effects of electrolytes regulating steroids on isolated rabbit atria, Am J Physiol 1959;127:1161-1164.
11. Bacciarelli C: L’cfTetto della digo-xina, del desossicorticosteronc e del-lo spironollatonc sul miocardo di mammifero, Arch Ini Pharmacodyn Ther 1967:166:150-166.
12. Béranger C, De Leiris J, Tapsoba A: Effets élcctrophysiologiques de l'association spironolactone-altizidc sur le cœur isolé de rat, Arch Mal Cœur Vaiss 1986;79:1117-1121.
13. Corabœuf S, Deroubaix E: Effect of a spironolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium, J Pharmacol Exp Ther 1974;191:128-138.
14. De Guzmann NT, Ych BK: Potassium canrenoate in the treatment of long-term digoxin-induced arrhythmias in conscious dogs, Am J Cardiol 1975:35:413-420.
15. Lamarche M, Royer R, Dupuis B, Tamisier JN: Etude expérimentale du canrénoatc de potassium sur la surcharge digitalique du myocarde: in: Extrarcnal Activity of Aldosterone and Its Antagonists, Amsterdam, Excerpta Medica, 1972, p 137.
16. Vlokler CM: Antiarrhythmic activity of various steroidal spironolactones in dogs, Proc Soc Exp Biol Med 1960:105:257-259.
17. Ych BK, Sung PK, Saha AK: Use of potassium canrenoate to suppress ouabain-induced ventricular arrhythmias in dogs, Circ Res 1972; 31:915-922.
18. Denis B, Machecourt J, Denis MC, Morena H, Pellet J, Rossignol R, Martin-Noël P: Intérêt du canréno-atc de potassium dans la prévention des troubles du rythme à la phase aiguë de l'infarctus de myocarde, Arch Mal Cœur Vaiss 1979;9:1014-1022.
19. Denis B, Denis MC, Machecourt J, Wolf JB, Dimitriou R, Page E, Bourlard P, Reboud JP: Potassium canre-noate in the prophylaxis of ventricular fibrillation in acute myocardial infarction; in Brunner HR, Berg-lund G, Brutsaert DL, Gardiner P, Ledingham JGG (eds): Contemporary Trends in Diuretic Therapy, Curr Clin Pract Ser, Amsterdam, Excerpta Medica, 1986, vol 35, pp 183-186.
20. Yeh BK, Chiang BN, Sung PK: An-liarrhythmic activity of potassium canrenoate in man, Am Heart J 1976:92:308-314.
21. Neely JR, Liebermeister H, Battcrs-by EJ, Morgan HE: Effects of pressure development oxygen consumption by the isolated rat heart, Am J Physiol 1967;212:804-814.
22. Bril A, Abadie C, Ben Baouali A, Maupoil V, Rochette L: Absence of relationship between antiarrhyth-mic effects of antidepressant drugs and lipid peroxidation, Pharmacology 1993:46:23-32.
23. Moreau D, Rochette L, Didier JP, Opie LH, Bralct J: Effects of increased heart work on release of norepinephrine and ventricular arrhythmias following reperfusion in the isolated rat heart, J Cardiovasc Pharmacol 1990:15:927-932.
24. Snedecor GW, Cochran WG: Statistical Methods, Ames, Iowa State University Press, 1980.
25. Fricke U: Lack of interaction of spironolactone with ouabain guinea pig isolated heart muscle preparation, EurJ Pharmacol 1978;49:363-371.
26. Welding M: Novel aldosterone receptors: Specificity-confering mechanism at the level of cell membrane, Steroids 1994;59:160-163.
27. Alexander EA, Levinsky NG: An ex-trarcnal mechanism of potassium adaptation, J Clin Invest 1968:47: 740-748.
28. Adler S: An extrarenal action of aldosterone on mammalian skeletal muscle, Am J Physiol 1970;218: 616-621.
29. Bia MJ, Tyler KA, DeFronzo RA: Regulation of extrarenal po'.assium homeostasis by adrenal hormones in rats, Am.1 Physiol 1982;242:F641-F648.
30. Jazayeri A, Meyer WJ: Mincralocor-ticoid-induccd increase in p-adren-ergic receptors of cultured rat arterial smooth muscle cells, J Steroid Biochem 1989;33:987-991.
31. Edelman IS, Fimognari GM: On the biochemical mechanism of action of aldosterone, Recent Prog Hcrm Res 1968;24:1-44.
32. 2Na efflux from arterial smooth muscle, Hypertension 1984: 6:425-430.
33. Oberleithner H, Wcigt M, West-phale HJ, Wang W: Aldosterone activates Na’/ll’ exchange and raises cytoplasmic pH in target cells of the amphibian kidney, Proc Natl Acad Sci USA 1987;84:1464-1468.
34. Welding M, Kasmayr J, Theisen K: Rapid effects of mineralocorticoids on sodium-proton exchanger: Genomic or nongenomic pathway? Am J Physiol 1991;260:E719-E726.
35. Wchling M, Ulsenheimer A, Schneider M, Neylon C, Christ M: Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: Subcellular localization of calcium elevations by single cell imaging, Biochem Biophys Res Commun 1994;204:475-481.
36. Welding M, Christ M, Theisen K: Hight affinity aldosterone binding to plasma membrane rich fractions from mononuclear leukocytes: Is there a membrane receptor for mineralocorticoids? Biochem Biophys Res Commun 1991:181:1306-1312.
37. Lombhs M, Rafestin-Oblin ME, Gasc JM, Farman N, Bonvalet JP: Immunohistochemical and biochemical characterization of mincr-alocorticoid receptors in the cardiovascular system; in: Aldosterone: Fundamental Aspects, Coll Inscrm, Paris, Libbey Eurotext, 1991, vol 215, p 337.
38. Bohr DF, Cummings G: Comparative potentiating action of various steroids on contraction of vascular smooth muscle, Fed Proc 1958:17: 17.
39. Bevegard S: The effect of four months’ treatment with spironolactone on systemic blood pressure, cardiac output and plasma renin activity in hypertensive patients, Acta McdScand 1977;202:373-377.
40. Clement DL: Peripheral action of spironolactone: Plethysmographic studies, Am J Cardiol 1990:65: 12K-13K.
41. Welding M: Aldosterone specific membrane receptors, rapid activation of the sodium-hydrogen exchanger, and cardiovascular implications, Cardiovasc Res 1995:29: 167-171.
42. Wehling M, Eisen C, Christ M: Membrane receptors for aldosterone: A new concept of nongenomic mineralocorticoid action, News Physiol Sci 1993:8:241-244.
43. Agarwal MK: Perspectives in receptor-mediated mineralocorticoid hormone action, Pharmacol Rev 1994: 46:67-87.
44. Weber KT, Brilla CG, Campbell SE, Reddy HK: Myocardial fibrosis and the concepts of cardioprotection and cardiopreparation, J Hypertcns 1992; 10(suppl):87-94.
45. Sherry JH, O’Donnel JP, Colby HD: Conversion of spironolactone to an active metabolite in target tissues: Formation of 7a-thiospironolactonc by microsomal preparations from guinea pig liver, adrenals, kidneys and testes, Life Sci 1981:29:2727-2736.
46. Gardiner P, Schrodc K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A: Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites, J Clin Pharmacol 1989:29:342-347.